tiprankstipranks
Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks
PremiumStock Analysis & IdeasOppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks
27d ago
Y-mAbs Therapeutics initiated with a Buy at Brookline on Danyelza potential
Premium
The Fly
Y-mAbs Therapeutics initiated with a Buy at Brookline on Danyelza potential
1M ago
Y-mAbs Therapeutics initiated with a Buy at Brookline
Premium
The Fly
Y-mAbs Therapeutics initiated with a Buy at Brookline
1M ago
Y-mAbs Therapeutics backs FY24 revenue view $87M-$95M, consensus $91.67M
PremiumThe FlyY-mAbs Therapeutics backs FY24 revenue view $87M-$95M, consensus $91.67M
2M ago
Is YMAB a Buy, Before Earnings?
Premium
Pre-Earnings
Is YMAB a Buy, Before Earnings?
2M ago
Y-mAbs Partners with Nobelpharma for Japan Expansion
Premium
Company Announcements
Y-mAbs Partners with Nobelpharma for Japan Expansion
2M ago
Y-mAbs Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe FlyY-mAbs Therapeutics initiated with an Overweight at Cantor Fitzgerald
5M ago
Y-mAbs Therapeutics price target lowered to $11 from $12 at Morgan Stanley
Premium
The Fly
Y-mAbs Therapeutics price target lowered to $11 from $12 at Morgan Stanley
5M ago
Y-mAbs Therapeutics price target lowered to $25 from $26 at BMO Capital
Premium
The Fly
Y-mAbs Therapeutics price target lowered to $25 from $26 at BMO Capital
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100